|
ES2620259T3
(es)
|
2010-04-14 |
2017-06-28 |
Roger Williams Medical Center |
Métodos y composiciones para tratar VIH
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
EA201391059A1
(ru)
*
|
2011-01-18 |
2014-05-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции для лечения рака и способы их применения
|
|
DK3473707T3
(da)
|
2012-05-25 |
2025-03-17 |
Cellectis |
Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
|
|
WO2014055442A2
(en)
*
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US10117896B2
(en)
*
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
KR102332790B1
(ko)
*
|
2013-02-15 |
2021-12-01 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
EP2958943B1
(en)
|
2013-02-20 |
2019-09-11 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
SG10201708896WA
(en)
*
|
2013-05-13 |
2017-11-29 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
IL305656A
(en)
*
|
2013-09-23 |
2023-11-01 |
Wilson Wolf Mfg Corporation |
Improved methods for genetic modification in animal cells
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
CA2934436A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
ES2764471T3
(es)
*
|
2014-02-14 |
2020-06-03 |
Univ Texas |
Receptores de antígeno quimérico y procedimientos de fabricación
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
JP2017515464A
(ja)
*
|
2014-04-10 |
2017-06-15 |
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
細胞免疫療法のための方法および組成物
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
LT3134432T
(lt)
|
2014-04-25 |
2020-04-10 |
Bluebird Bio, Inc. |
Mnd promotorius chimerinių antigenų receptoriams
|
|
JP6817069B2
(ja)
|
2014-04-25 |
2021-01-20 |
ブルーバード バイオ， インコーポレイテッド |
養子細胞療法薬を製造するための改善された方法
|
|
CN107074929B
(zh)
|
2014-05-02 |
2021-09-03 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
|
CN106793780B
(zh)
*
|
2014-06-06 |
2020-05-26 |
蓝鸟生物公司 |
改善的t细胞组合物
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
SG11201700418VA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
|
WO2016014789A2
(en)
|
2014-07-24 |
2016-01-28 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP3174556A1
(en)
*
|
2014-07-29 |
2017-06-07 |
Pfizer Inc |
EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
HRP20201128T1
(hr)
*
|
2014-11-05 |
2020-10-30 |
Juno Therapeutics, Inc. |
Postupci za transdukciju i obradu stanica
|
|
WO2016094304A2
(en)
|
2014-12-12 |
2016-06-16 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
CN108064252A
(zh)
|
2014-12-19 |
2018-05-22 |
达纳－法伯癌症研究所公司 |
嵌合抗原受体及其使用方法
|
|
AU2015374296B2
(en)
|
2014-12-29 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
MX389057B
(es)
|
2015-01-26 |
2025-03-20 |
Allogene Therapeutics Inc |
Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
IL287914B2
(en)
|
2015-02-24 |
2025-10-01 |
Univ California |
Linkage-activated transcription switches and methods of using them
|
|
EP3273976B1
(en)
|
2015-03-27 |
2023-07-26 |
President and Fellows of Harvard College |
Modified t cells and methods of making and using the same
|
|
SG11201708191XA
(en)
|
2015-04-08 |
2017-11-29 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3294893B1
(en)
*
|
2015-05-13 |
2023-12-27 |
CSL Behring Gene Therapy, Inc. |
Bio-production of lentiviral vectors
|
|
PT3298033T
(pt)
|
2015-05-18 |
2020-09-22 |
Tcr2 Therapeutics Inc |
Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
|
|
CA2986798A1
(en)
*
|
2015-05-28 |
2016-12-01 |
Kite Pharma, Inc. |
Methods of conditioning patients for t cell therapy
|
|
EP4218778A3
(en)
|
2015-05-28 |
2023-08-23 |
Kite Pharma, Inc. |
Diagnostic methods for t cell therapy
|
|
WO2017011670A1
(en)
*
|
2015-07-16 |
2017-01-19 |
Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center |
Compositions and methods for treating peritoneal cancers
|
|
CN109476722A
(zh)
|
2015-07-21 |
2019-03-15 |
诺华股份有限公司 |
用于改善免疫细胞的功效和扩张的方法
|
|
AU2016306209B2
(en)
|
2015-08-07 |
2023-07-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific CAR T-cells for solid tumor targeting
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
AU2016341966A1
(en)
|
2015-10-20 |
2018-05-10 |
Kite Pharma, Inc. |
Methods of preparing T cells for T cell therapy
|
|
CN108289913A
(zh)
|
2015-10-30 |
2018-07-17 |
儿童国家医疗中心 |
从未致敏t细胞群体产生hpv抗原特异性t细胞
|
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
HUE052016T2
(hu)
*
|
2015-11-19 |
2021-04-28 |
Novartis Ag |
Pufferek lentivírus prepartátumok stabilizálására
|
|
US20210206826A1
(en)
*
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
ES2988976T3
(es)
|
2015-11-27 |
2024-11-22 |
Cartherics Pty Ltd |
Células modificadas genéticamente y usos de estas
|
|
CN121294437A
(zh)
|
2015-12-04 |
2026-01-09 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
CN116334113A
(zh)
|
2016-01-08 |
2023-06-27 |
加利福尼亚大学董事会 |
有条件活性的异二聚体多肽及其使用方法
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
SI3436079T1
(sl)
|
2016-04-01 |
2022-01-31 |
Kite Pharma, Inc. |
Himerni antigen in T celični receptorji ter način uporabe
|
|
KR102522622B1
(ko)
|
2016-04-01 |
2023-04-18 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
|
ES2930058T3
(es)
|
2016-04-01 |
2022-12-05 |
Kite Pharma Inc |
Receptores quiméricos y métodos de uso de los mismos
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
EP3445407B1
(en)
|
2016-04-22 |
2022-12-14 |
CRAGE medical Co., Limited |
Compositions and methods of cellular immunotherapy
|
|
CN118146379B
(zh)
*
|
2016-04-26 |
2025-09-09 |
恺兴生命科技(上海)有限公司 |
一种改善免疫应答细胞功能的方法
|
|
TW202434312A
(zh)
|
2016-05-13 |
2024-09-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
JP7373991B2
(ja)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
CN109689686B
(zh)
|
2016-10-07 |
2020-08-25 |
T细胞受体治疗公司 |
使用融合蛋白进行t细胞受体重编程的组合物和方法
|
|
SG10201913823VA
(en)
|
2016-10-07 |
2020-03-30 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
MX2019005277A
(es)
|
2016-11-04 |
2019-09-27 |
Bluebird Bio Inc |
Composiciones de celulas t con car anti-bcma.
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3551197B1
(en)
|
2016-12-12 |
2023-11-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
EP3583129B1
(en)
|
2017-02-14 |
2021-11-03 |
Kite Pharma, Inc. |
Cd70 binding molecules and methods of use thereof
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
KR102692556B1
(ko)
|
2017-03-16 |
2024-08-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 변이체 면역조절 단백질 및 그의 용도
|
|
MX2019010887A
(es)
|
2017-03-16 |
2019-10-15 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de cb80 variante y usos de estas.
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
AU2018237159A1
(en)
|
2017-03-22 |
2019-09-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
EP3600408A1
(en)
*
|
2017-03-27 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Improved antigen binding receptor formats
|
|
CA3054443A1
(en)
|
2017-04-01 |
2018-10-14 |
Avm Biotechnology, Llc |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
|
EP3655022A1
(en)
|
2017-04-03 |
2020-05-27 |
Kite Pharma, Inc. |
Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
SG10202112528QA
(en)
|
2017-05-12 |
2021-12-30 |
Jackson Lab |
Nsg mice lacking mhc class i and class ii
|
|
ES3000510T3
(en)
|
2017-06-09 |
2025-02-28 |
Providence Health & Services Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
MX2020001490A
(es)
*
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
|
|
CN114533863A
(zh)
*
|
2017-09-15 |
2022-05-27 |
凯德药业股份有限公司 |
用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
KR20230007557A
(ko)
|
2017-09-22 |
2023-01-12 |
카이트 파마 인코포레이티드 |
키메라 폴리펩티드 및 그의 용도
|
|
EP4442268A3
(en)
|
2017-10-10 |
2025-04-02 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
MX421741B
(es)
|
2017-10-18 |
2025-03-14 |
Kite Pharma Inc |
Inmunoterapia con receptores de antígeno quimérico y uso de la misma
|
|
WO2019079520A2
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
CN111683962B
(zh)
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
CA3086832A1
(en)
|
2018-01-03 |
2019-07-11 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
KR20200110356A
(ko)
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
|
AU2019209432B2
(en)
|
2018-01-22 |
2026-01-08 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
AU2019222550B2
(en)
|
2018-02-16 |
2022-10-27 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
US10780120B2
(en)
|
2018-03-06 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
US11873335B2
(en)
|
2018-03-13 |
2024-01-16 |
Phanes Therapeutics, Inc. |
Anti-folate receptor 1 antibodies and uses thereof
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
SG11202009881WA
(en)
|
2018-04-12 |
2020-11-27 |
Kite Pharma Inc |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
KR102734592B1
(ko)
|
2018-06-01 |
2024-11-27 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 t 세포 요법
|
|
CA3101028A1
(en)
|
2018-06-05 |
2019-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020005837A1
(en)
*
|
2018-06-25 |
2020-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
WO2020016661A2
(en)
|
2018-07-09 |
2020-01-23 |
Multitude Inc. |
Antibodies specific to folate receptor alpha
|
|
SG11202101014XA
(en)
|
2018-08-02 |
2021-02-25 |
Kite Pharma Inc |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
BR112021006784A2
(pt)
*
|
2018-10-10 |
2021-09-21 |
Zymeworks Inc. |
Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos
|
|
CN116286665A
(zh)
*
|
2018-11-16 |
2023-06-23 |
上海煦顼技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
EP3883585A4
(en)
*
|
2018-11-20 |
2022-12-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
|
|
JP7278379B2
(ja)
|
2018-11-29 |
2023-05-19 |
ヴィネティ インク． |
集中型及び分散型の個別化医薬プラットフォーム
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
CA3122762A1
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
CA3132840A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
|
TW202042824A
(zh)
*
|
2019-03-27 |
2020-12-01 |
賓夕法尼亞大學董事會 |
Tn-MUC1嵌合抗原受體（CAR）T細胞療法
|
|
CA3138707A1
(en)
|
2019-05-03 |
2020-11-12 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
CN121204097A
(zh)
*
|
2019-05-13 |
2025-12-26 |
宾夕法尼亚大学董事会 |
乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
|
|
EP3973072A1
(en)
|
2019-05-23 |
2022-03-30 |
Vogelsang, Matjaz |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
US20220259284A1
(en)
|
2019-06-12 |
2022-08-18 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
WO2020257823A2
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
BR112022003852A2
(pt)
|
2019-09-03 |
2022-05-31 |
Allogene Therapeutics Inc |
Métodos de preparação de células t para terapia de células t
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
AU2020361683A1
(en)
*
|
2019-10-11 |
2022-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
|
|
JP2022553200A
(ja)
*
|
2019-10-16 |
2022-12-22 |
ウモジャ バイオファーマ， インコーポレイテッド |
ユニバーサル受容体療法のためのレトロウイルスベクター
|
|
JP2023503161A
(ja)
|
2019-11-26 |
2023-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
JP7714545B2
(ja)
|
2019-11-26 |
2025-07-29 |
ノバルティス アーゲー |
キメラ抗原受容体及びその使用
|
|
MX2022007598A
(es)
|
2019-12-20 |
2022-09-23 |
Instil Bio Uk Ltd |
Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
AU2021308702A1
(en)
|
2020-07-17 |
2023-03-16 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
IL299911A
(en)
|
2020-08-14 |
2023-03-01 |
Kite Pharma Inc |
Improving immune cell function
|
|
JP2023541368A
(ja)
*
|
2020-08-18 |
2023-10-02 |
デルフィ ダイアグノスティックス インコーポレイテッド |
がんを評価するための無細胞ｄｎａ断片サイズ密度のための方法及びシステム
|
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
AU2021347320A1
(en)
|
2020-09-24 |
2023-05-11 |
The Jackson Laboratory |
Humanized mouse models for assessing immune cell therapy
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
AU2021410635A1
(en)
|
2020-12-24 |
2023-06-29 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
|
JP7580616B2
(ja)
|
2021-01-10 |
2024-11-11 |
カイト ファーマ インコーポレイテッド |
Ｔ細胞療法
|
|
US20220265719A1
(en)
|
2021-02-20 |
2022-08-25 |
Kite Pharma, Inc. |
Immunotherapies
|
|
JP7690597B2
(ja)
|
2021-03-11 |
2025-06-10 |
カイト ファーマ インコーポレイテッド |
免疫細胞機能の改善
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
US12337035B2
(en)
|
2021-04-16 |
2025-06-24 |
Kite Pharma, Inc. |
TACI binding molecules
|
|
CN117203328A
(zh)
|
2021-04-27 |
2023-12-08 |
武田药品工业株式会社 |
重组抗原呈递细胞
|
|
IL308227A
(en)
|
2021-05-14 |
2024-01-01 |
Kite Pharma Inc |
Chimeric antigen receptor t cell therapy
|
|
CA3221231A1
(en)
|
2021-05-24 |
2022-12-01 |
Kite Pharma, Inc. |
Chimeric antigen receptor
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
EP4352102A1
(en)
|
2021-06-08 |
2024-04-17 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
US11945876B2
(en)
|
2021-06-16 |
2024-04-02 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
EP4363558A1
(en)
*
|
2021-07-01 |
2024-05-08 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
IL309431A
(en)
|
2021-07-02 |
2024-02-01 |
Kite Pharma Inc |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
|
EP4370213A4
(en)
|
2021-07-16 |
2025-06-04 |
Instil Bio (Uk) Limited |
Chimeric molecules for targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
KR20250005566A
(ko)
|
2021-12-30 |
2025-01-09 |
티알1엑스, 인크. |
Il-10 및 키메라 항원 수용체를 발현하는 cd4+ t 세포 및 이의 용도
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20230296610A1
(en)
|
2022-02-15 |
2023-09-21 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
|
EP4490173A1
(en)
|
2022-03-07 |
2025-01-15 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
IL316709A
(en)
|
2022-06-09 |
2024-12-01 |
Kite Pharma Inc |
Methods for preparing lymphocytes for cell therapy
|
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024092227A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|
|
KR20250162836A
(ko)
|
2023-03-17 |
2025-11-19 |
카이트 파마 인코포레이티드 |
종양 미세환경이 면역요법의 효능에 미치는 영향
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
TW202506996A
(zh)
|
2023-04-27 |
2025-02-16 |
日商武田藥品工業股份有限公司 |
擴增ｃｄ５６＋／ｃｄ３－細胞之方法
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
US20250161361A1
(en)
|
2023-11-01 |
2025-05-22 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
US20250290154A1
(en)
|
2024-03-04 |
2025-09-18 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|